Impact of Sacubitril/ Valsartan on Quality Of Life and Ejection fraction of Heart Failure patients with and without Chronic Kidney Disease

  • Huma Zartash Syeda Royal college of physicians UK
  • Sidra Saleem
  • Abeera Mansur
  • Zain Rasool
  • Shahryar Ahmad Sheikh
Keywords: Sacubitril, Valsartan, Heart failure, Chronic Kidney disease, Quality of Life

Abstract

Objective: Chronic kidney disease (CKD) patients are at high risk of heart failure (HF) and both share similar risk factors, including diabetes and elevated blood Pressure (B.P). Aim of this study was to determine the impact of sacubitril/valsartan on the quality of life (QOL) and ejection fraction (EF) of patients with HF with and without CKD.

Methods: Single center (Doctors Hospital Lahore), observational study with longitudinal follow up, on 104 HF patients from July 2019 to July 2020. HF was diagnosed on both clinical and echo parameters. New York Heart Association Class II-IV, EF less than or equal to 40% HF with reduced EF and stage three CKD patients were included. Sacubitril/Valsartan was prescribed at a starting daily dose of 50mg and then up titrated to 400mg. Patients were followed up with clinical evaluation, QOL assessment, echocardiography and biochemical profile at one, four, eight and 12 months.

Results: Gender, age, and diabetes mellitus between CKD and non-CKD patients were noted to be statistically different, defined as p<0.05. CKD patients’ QOL increased from 45.15 to 57.57 from baseline to 12 months (p-value<0.01). Non-CKD patients’ QOL increased from 48.07 to 56.25. In CKD patients, EF increased from 27.87% to 29.29% from baseline to 12 months (p-value 0.03) whereas in non-CKD patients EF improved from 29.42% to 31.43%.

Conclusion: Sacubitril/ valsartan improves QOL in patients of HF with reduced EF both with and without CKD. Clinical improvement was independent of Left Ventricular EF as measured by QOL. Thus, QOL is a useful tool to assess the drug’s beneficial effect.

doi: https://doi.org/10.12669/pjms.40.6.7892

How to cite this: Zartash SH, Saleem S, Mansur A, Rasool Z, Sheikh SA. Impact of Sacubitril/ Valsartan on quality of life and ejection fraction of heart failure patients with and without chronic kidney disease. Pak J Med Sci. 2024;40(6):1049-1053. doi: https://doi.org/10.12669/pjms.40.6.7892

This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Published
2024-05-20
How to Cite
Syeda, H. Z., Saleem, S., Mansur, A., Rasool, Z., & Sheikh, S. A. (2024). Impact of Sacubitril/ Valsartan on Quality Of Life and Ejection fraction of Heart Failure patients with and without Chronic Kidney Disease. Pakistan Journal of Medical Sciences, 40(6). https://doi.org/10.12669/pjms.40.6.7892
Section
Original Articles